This report describes and explains the osteoporosis drugs market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global osteoporosis drugs market reached a value of nearly $12.88 billion in 2024, having grown at a compound annual growth rate (CAGR) of 2.42% since 2019. The market is expected to grow from $12.88 billion in 2024 to $15.69 billion in 2029 at a rate of 4.02%. The market is then expected to grow at a CAGR of 4.77% from 2029 and reach $19.8 billion in 2034.
Growth in the historic period resulted from the health insurance expansion, increase in bone fractures and comorbidities and government and health initiatives. Factors that negatively affected growth in the historic period were safety concerns.
Going forward, increasing aging population, rising healthcare expenditure, economic growth in emerging markets and rising prevalence of osteoporosis will drive the growth. Factor that could hinder the growth of the osteoporosis market in the future include high costs.
The global osteoporosis drugs market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 39.7% of the total market in 2023. Amgen Inc. was the largest competitor with a 9.33% share of the market, followed by Eli Lilly and Company with 4.29%, Pfizer Inc. 3.76%, Eisai Co., Ltd. with 3.73%, Apotex Inc. with 3.65%, AbbVie Inc. with 3.33%, Novartis AG with 3.32%, Sanofi S.A. with 3.01%, GSK plc with 2.78% and Daiichi Sankyo Company, Limited with 2.52%.
North America was the largest region in the osteoporosis drugs market, accounting for 43.50% or $5.6 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the osteoporosis drugs market will be Asia Pacific and South America where growth will be at CAGRs of 5.73% and 4.44% respectively. These will be followed by Eastern Europe and Western Europe where the markets are expected to grow at CAGRs of 4.25% and 3.58% respectively.
The osteoporosis drugs market is segmented by type into bisphosphonates, selective estrogen receptor modulators (SERMs), RANK ligand inhibitors, parathyroid hormone therapy, calcitonin, sclerostin inhibitor and other drug class. The bisphosphonates market was the largest segment of the osteoporosis drugs market segmented by type, accounting for 34.45% or $4.43 billion of the total in 2024. Going forward, the RANK ligand inhibitors segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by type, at a CAGR of 4.76% during 2024-2029.
The osteoporosis drugs market is segmented by administration into oral and injectable. The oral market was the largest segment of the osteoporosis drugs market segmented by administration, accounting for 57.71% or $7.43 billion of the total in 2024. Going forward, the injectable segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by administration, at a CAGR of 4.71% during 2024-2029.
The osteoporosis drugs market is segmented by distribution channel into retail pharmacies, hospital pharmacies and online sales. The hospital pharmacies market was the largest segment of the osteoporosis drugs market segmented by distribution channel, accounting for 42.89% or $5.52 billion of the total in 2024. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by distribution channel, at a CAGR of 4.50% during 2024-2029.
The osteoporosis drugs market is segmented by application into primary osteoporosis and secondary osteoporosis. The primary osteoporosis market was the largest segment of the osteoporosis drugs market segmented by application, accounting for 78.19% or $10.07 billion of the total in 2024. Going forward, the primary osteoporosis segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by application, at a CAGR of 4.11% during 2024-2029.
The top opportunities in the osteoporosis drugs markets segmented by type will arise in the bisphosphonates segment, which will gain $1.07 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs market segmented by administration will arise in the oral segment, which will gain $1.39 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by distribution channel will arise in the retail pharmacies segment, which will gain $1.12 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by application will arise in the primary osteoporosis segment, which will gain $2.24 billion of global annual sales by 2029. The osteoporosis drugs market size will gain the most in USA at $870.53 million.
Market-trend-based strategies for the osteoporosis drugs market include focus on developing innovative solutions, such as teriparatide Injection for the treatment of treatment osteoporosis, development of innovative solutions, such as obtaining regulatory approvals and advancing innovative treatment solutions, such as edirol tablet for osteoporosis treatment.
Player-adopted strategies in the osteoporosis drugs market include focus on expanding business capabilities through the launch of new products.
To take advantage of the opportunities, the analyst recommends the osteoporosis drugs companies to focus on developing innovative and accessible treatment solutions, focus on regulatory approvals and innovative treatments, focus on enhancing medication adherence and targeted therapeutic options, focus on RANK ligand inhibitors for business growth, focus on the injectable segment for growth, expand in emerging markets, focus on expanding distribution channels for osteoporosis drugs, focus on developing competitive and flexible pricing strategies for osteoporosis drugs, focus on targeted marketing and educational campaigns for osteoporosis drugs, focus on physician engagement and influencer collaborations for osteoporosis drugs, focus on online sales for growth in osteoporosis drugs market and focus on primary osteoporosis market segment.
The global osteoporosis drugs market reached a value of nearly $12.88 billion in 2024, having grown at a compound annual growth rate (CAGR) of 2.42% since 2019. The market is expected to grow from $12.88 billion in 2024 to $15.69 billion in 2029 at a rate of 4.02%. The market is then expected to grow at a CAGR of 4.77% from 2029 and reach $19.8 billion in 2034.
Growth in the historic period resulted from the health insurance expansion, increase in bone fractures and comorbidities and government and health initiatives. Factors that negatively affected growth in the historic period were safety concerns.
Going forward, increasing aging population, rising healthcare expenditure, economic growth in emerging markets and rising prevalence of osteoporosis will drive the growth. Factor that could hinder the growth of the osteoporosis market in the future include high costs.
The global osteoporosis drugs market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 39.7% of the total market in 2023. Amgen Inc. was the largest competitor with a 9.33% share of the market, followed by Eli Lilly and Company with 4.29%, Pfizer Inc. 3.76%, Eisai Co., Ltd. with 3.73%, Apotex Inc. with 3.65%, AbbVie Inc. with 3.33%, Novartis AG with 3.32%, Sanofi S.A. with 3.01%, GSK plc with 2.78% and Daiichi Sankyo Company, Limited with 2.52%.
North America was the largest region in the osteoporosis drugs market, accounting for 43.50% or $5.6 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the osteoporosis drugs market will be Asia Pacific and South America where growth will be at CAGRs of 5.73% and 4.44% respectively. These will be followed by Eastern Europe and Western Europe where the markets are expected to grow at CAGRs of 4.25% and 3.58% respectively.
The osteoporosis drugs market is segmented by type into bisphosphonates, selective estrogen receptor modulators (SERMs), RANK ligand inhibitors, parathyroid hormone therapy, calcitonin, sclerostin inhibitor and other drug class. The bisphosphonates market was the largest segment of the osteoporosis drugs market segmented by type, accounting for 34.45% or $4.43 billion of the total in 2024. Going forward, the RANK ligand inhibitors segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by type, at a CAGR of 4.76% during 2024-2029.
The osteoporosis drugs market is segmented by administration into oral and injectable. The oral market was the largest segment of the osteoporosis drugs market segmented by administration, accounting for 57.71% or $7.43 billion of the total in 2024. Going forward, the injectable segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by administration, at a CAGR of 4.71% during 2024-2029.
The osteoporosis drugs market is segmented by distribution channel into retail pharmacies, hospital pharmacies and online sales. The hospital pharmacies market was the largest segment of the osteoporosis drugs market segmented by distribution channel, accounting for 42.89% or $5.52 billion of the total in 2024. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by distribution channel, at a CAGR of 4.50% during 2024-2029.
The osteoporosis drugs market is segmented by application into primary osteoporosis and secondary osteoporosis. The primary osteoporosis market was the largest segment of the osteoporosis drugs market segmented by application, accounting for 78.19% or $10.07 billion of the total in 2024. Going forward, the primary osteoporosis segment is expected to be the fastest growing segment in the osteoporosis drugs market segmented by application, at a CAGR of 4.11% during 2024-2029.
The top opportunities in the osteoporosis drugs markets segmented by type will arise in the bisphosphonates segment, which will gain $1.07 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs market segmented by administration will arise in the oral segment, which will gain $1.39 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by distribution channel will arise in the retail pharmacies segment, which will gain $1.12 billion of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by application will arise in the primary osteoporosis segment, which will gain $2.24 billion of global annual sales by 2029. The osteoporosis drugs market size will gain the most in USA at $870.53 million.
Market-trend-based strategies for the osteoporosis drugs market include focus on developing innovative solutions, such as teriparatide Injection for the treatment of treatment osteoporosis, development of innovative solutions, such as obtaining regulatory approvals and advancing innovative treatment solutions, such as edirol tablet for osteoporosis treatment.
Player-adopted strategies in the osteoporosis drugs market include focus on expanding business capabilities through the launch of new products.
To take advantage of the opportunities, the analyst recommends the osteoporosis drugs companies to focus on developing innovative and accessible treatment solutions, focus on regulatory approvals and innovative treatments, focus on enhancing medication adherence and targeted therapeutic options, focus on RANK ligand inhibitors for business growth, focus on the injectable segment for growth, expand in emerging markets, focus on expanding distribution channels for osteoporosis drugs, focus on developing competitive and flexible pricing strategies for osteoporosis drugs, focus on targeted marketing and educational campaigns for osteoporosis drugs, focus on physician engagement and influencer collaborations for osteoporosis drugs, focus on online sales for growth in osteoporosis drugs market and focus on primary osteoporosis market segment.
Major Market Trends
- Innovative Osteoporosis Treatment Launched To Enhance Patient Outcomes
- Innovative Approaches and Regulatory Approvals Driving Treatment Advancements
- Advance Treatment With Targeted Therapeutic Option For Better Osteoporosis Treatment
Key Mergers and Acquisitions
- Bone Health Technologies Acquired Wellen
- Nestlé Health Science Acquired Bountiful Company
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Osteoporosis Drugs Market - Macro Economic Scenario
9 Global Market Size and Growth
10 Global Osteoporosis Drugs Market Segmentation
11 Osteoporosis Drugs Market, Regional and Country Analysis
12 Asia-Pacific Market
13 Western Europe Market
14 Eastern Europe Market
15 North America Market
16 South America Market
17 Middle East Market
18 Africa Market
19 Competitive Landscape and Company Profiles
20 Other Major and Innovative Companies
23 Key Mergers and Acquisitions
24 Opportunities and Strategies
25 Osteoporosis Drugs Market, Conclusions and Recommendations
26 Appendix
Executive Summary
Osteoporosis Drugs Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global osteoporosis drugs market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for osteoporosis drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider osteoporosis drugs market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by administration, by distribution channel and by application.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the osteoporosis drugs market.
- Global Market Size And Growth - Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by administration, by distribution channel and by application in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for osteoporosis drugs providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors; Parathyroid Hormone Therapy; Calcitonin; Sclerostin Inhibitor; Other Drug Class2) By Administration: Oral; Injectable
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
4) By Application: Primary Osteoporosis; Secondary Osteoporosis
Key Companies Mentioned: Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; Eisai Co., Ltd.; Apotex Inc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; osteoporosis drugs indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
The major companies featured in this Osteoporosis Drugs market report include:- Donaldson Company Inc.
- Freudenberg Filtration Technologies SE & Co. KG
- Parker Hannifin Corp.
- Entegris Inc.
- American Air Filter Company Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi S.A.
- GSK plc
- Daiichi Sankyo Company, Limited
- Takeda Pharmaceutical Company
- Teva Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Merck Sharp & Dohme
- Roche Holding AG
- Transcenta Holding Ltd.
- Shanghai Henlius Biotech
- Enzene Biosciences Ltd.
- Eden Biologics
- Zydus Lifesciences
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Strides Pharma Science
- Asahi Kasei Corporation
- Pharmac
- Axial Therapeutics
- Acrux Limited
- Cynata Therapeutics
- Kyowa Kirin
- Cadila Pharmaceuticals
- Luye Pharma Group
- Pharmed Limited
- Chugai Pharmaceutical Co. Ltd.
- Towa Pharmaceutical Co., Ltd.
- GlaxoSmithKline plc
- UCB S.A.
- Sandoz AG
- Enzene Biosciences Limited
- Fresenius Kabi
- Gedeon Richter
- Alvotech
- Mabxience Holding, S.L.
- Theramex
- Novo Nordisk A/S
- Bristol Myers Squibb
- Ferring Pharmaceuticals
- Laboratoires Servier
- Grunenthal GmbH
- OsteoSys
- Medimaps Group SA
- Pharmanovia
- Glenmark Pharmaceuticals
- Dr. Max Group
- Polpharma
- Celon Pharma
- Hasco-Lek
- Biofarma S.A.
- Sandoz
- Mylan Pharmaceuticals
- Radius Health, Inc.
- Horizon Therapeutics
- Levolta Pharmaceuticals, Inc.
- Tabuk Pharmaceuticals
- EVA Pharma
- AstraZeneca
- Abbott Laboratories
- Adcock Ingram
- Aspen Pharmacare Holdings Limited
- IBN SINA Pharmaceutical
- Solal Technologies
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 317 |
Published | March 2025 |
Forecast Period | 2024 - 2034 |
Estimated Market Value ( USD | $ 12.88 Billion |
Forecasted Market Value ( USD | $ 19.8 Billion |
Compound Annual Growth Rate | 4.4% |
Regions Covered | Global |
No. of Companies Mentioned | 70 |